BioLargo, Inc. (BLGO)
| Market Cap | 34.23M -33.8% |
| Revenue (ttm) | 5.61M -65.6% |
| Net Income | -12.91M |
| EPS | -0.04 |
| Shares Out | 321.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,981 |
| Open | 0.1080 |
| Previous Close | 0.1060 |
| Day's Range | 0.10474 - 0.1093 |
| 52-Week Range | 0.0950 - 0.2337 |
| Beta | -0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies in the United States. The company’s technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances (PFAS) water contamination; advanced water and wastewater treatment; industrial odor and volatile organic compounds control, air quality control, and infection control; and myriad environmental remediation. It provides full-service environmental engineering, battery energy storage, and advanced antimicrobial medical device platf... [Read more]
Financial Performance
In 2025, BioLargo's revenue was $7.77 million, a decrease of -56.32% compared to the previous year's $17.78 million. Losses were -$11.78 million, 390.4% more than in 2024.
Financial StatementsNews
BioLargo's Lake Stockholm AEC Installation passes six months of PFAS remediation Topping Two Million Gallons
The patented AEC removes more than 99% of PFAS chemicals in water, consistently exceeding state and federal requirements, and generates a fraction of the waste of conventional methods. WESTMINSTER, CA...
BioLargo joins NJIT-led PFAS Partnership Innovation Consortium
BioLargo (BLGO) has joined the New Jersey PFAS Partnership Innovation Consortium an NJIT-led initiative focused on accelerating the development, validation, and deployment of PFAS technologies. BioLar...
BioLargo Joins New Jersey Institute of Technology-Led PFAS Consortium; President Tonya Chandler Appointed to Board of Directors
Company to contribute commercial PFAS treatment expertise alongside leading universities, regulators, utilities, and industry organizations advancing next-generation PFAS solutions. WESTMINSTER, CA / ...
BioLargo Equipment Solutions & Technologies' "PFAS Lady" to Teach PFAS 101 at 41st Annual Tri-State Seminar
Tonya Chandler will lead a seven-hour continuing education course for the fourth consecutive year at one of the water industry's largest regional gatherings WESTMINSTER, CA / ACCESS Newswire / July 29...
BioLargo PFAS Treatment Technology Featured in The Disruptive Quarterly
Company leaders join environmental attorneys, academic researchers, and industry innovators in a special issue on forever chemicals and the protection of clean water WESTMINSTER, CA / ACCESS Newswire ...
BioLargo preparing to relaunch CupriDyne-based consumer products
BioLargo (BLGO) is preparing to relaunch CupriDyne-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into...
BioLargo Relaunching CupriDyne(R)-Based Consumer Products - Back by Popular Demand and Generated More than $125 Million in Pet-Care Sales
BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the or...
BioLargo Engineering Unit Awarded $1.4 Million in U.S. Air Force Environmental Contract Renewals
BLEST Renews Air Quality Compliance Work at Five Air Force Bases Across New Mexico and Arizona WESTMINSTER, CA / ACCESS Newswire / July 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life scie...
BioLargo Quarterly report: Q1 2026
BioLargo has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioLargo Transcript: Status update
A strategic partnership with Aquatech is accelerating PFAS solution commercialization, with a robust pipeline and global engagement. Clyra is nearing a major product launch, while Cellinity advances battery tech and financing. Operational efficiency and IP protection remain priorities.
BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
Agreement Extends Clyra's International Reach Through One of the Region's Premier Healthcare Distributors WESTMINSTER, CA / ACCESS Newswire / May 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and...
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology
WESTMINSTER, CA / ACCESS Newswire / May 4, 2026 / BioLargo Equipment Solutions & Technologies, Inc. ("BioLargo Equipment"), a subsidiary of BioLargo, Inc. (OTCQX:BLGO), an environmental engineering co...
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
A meeting transcript will be published by 8-K prior to the market open the next day WESTMINSTER, CA / ACCESS Newswire / May 4, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovat...
BioLargo awarded $1.2M contract to design minerals processing facility
BioLargo’s (BLGO) BioLargo Engineering, Science & Technologies has been awarded a $1.2M contract to design a pilot-scale minerals processing facility that will support the remediation and beneficial r...
BioLargo Engineering, Science & Technologies Awarded $1.2 Million Contract to Design Pilot-Scale Minerals Processing Facility for Resource Recovery
WESTMINSTER, CA / ACCESS Newswire / April 20, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator focused on sustainable water and environmental solutions, announced that its engineering subsidi...
BioLargo Registration statement: Registration filing
BioLargo filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
BioLargo Registration statement: Registration filing
BioLargo filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
BioLargo CEO Dennis Calvert to Present Global Environmental Leadership Award to Robert Bilott at Nassau County PFAS Forum
BioLargo sponsors legal and technical forum on PFAS contamination; company's PFAS remediation technology to be featured on a technical panel alongside leading environmental engineering firms, followed...
BioLargo Earnings Call Transcript: Q4 2025
2025 saw a revenue decline to $7.8M and a $15.2M net loss, mainly due to the Pooph license termination, but strong liquidity and service revenue growth were maintained. Clyra Medical entered commercialization, AEC achieved regulatory validation, and Cellinity Battery advanced joint ventures, positioning for a transformative 2026.
BioLargo Annual report: Q4 2025
BioLargo has published its Q4 2025 annual report on March 5, 2026.
BioLargo Slides: Q4 2025
BioLargo has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
BioLargo Reports Annual 2025 Operating and Financial Results
A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments with $3.9 Million Cash Balance at Year End WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 5, 2026 ...
BioLargo Q4 2025 and Year End Earnings Results Webcast and Conference Call on Thursday, March 5th, 2026 - 12:00 PM Eastern Time
WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 4, 2026 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will h...
BioLargo’s Clyra Medical highlights KOL presentation on ViaCLYR results
BioLargo (BLGO) announced that clinical experience with ViaCLYR, Clyra Medical Technologies’ advanced wound irrigation solution powered by its proprietary Clyrasept technology, was presented on Januar...
BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium
Clinical Experience Presented at Boswick Symposium Shows Rapid Wound Transformation, Enhanced Healing, and Strong Antimicrobial Performance Across Multiple Wound Types WESTMINSTER, CALIFORNIA / ACCESS...